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Abstract
Primary mucinous ovarian carcinomas (MOC) are notoriously difficult to distinguish from mucinous carcinomas metastatic to the
ovary (mMC). Studies performed on small cohorts reported algorithms based on tumor size and laterality to aid in distinguishing
MOC from mMC. We evaluated and improved these by performing a large-scale, nationwide search in the Dutch Pathology
Registry. All registered pathology reports fulfilling our search criteria concerning MOC in the Netherlands from 2000 to 2011 were
collected. Age, histology, laterality, and size were extracted. An existing database covering the same timeline containing tumors
metastatic to the ovary was used, extracting all mMC, age, size, laterality, and primary tumor location. Existing algorithms were
applied to our cohort. Subsequently, an algorithm based on tumor histology, laterality, and a nomogram based on age and size was
created for differentiatingMOC andmMC.We identified 735MOC and 1018mMC. Patients withMOCwere significantly younger
and MOC were significantly larger and more often unilateral than mMC. Signet ring cell carcinomas were rarely primary. Our
algorithm used signet ring cell histology, bilaterality, and a nomogram integrating patient age and tumor size to diagnose mMC.
Sensitivity and specificity for mMC was 90.1% and 59.0%, respectively. Applying existing algorithms on our cohort yielded a far
lower sensitivity. The algorithm described here using tumor histology, laterality, size, and patient age has higher sensitivity but lower
specificity compared to earlier algorithms and aids in indicating tumor origin, but for conclusive diagnosis, careful integration of
morphology, immunohistochemistry, and clinical and imaging data is recommended.
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Introduction
It is well known that a considerable part of mucinous ovar-
ian carcinomas are in fact metastases, mainly from the gas-
trointestinal tract, pancreas, and gallbladder [1–4]. The dis-
tinction of primary mucinous carcinomas of the ovary
(MOC) and mucinous carcinomas metastatic to the ovary
(mMC) might be difficult and misdiagnosis has important
consequences for therapy. Chemotherapy regimens differ
between tumor types and advanced stage MOC are gener-
ally associated with a poor response to treatment [5].
Although certain histological features may be indicative
of primary or metastatic origin, these are often inconclu-
sive [6–9]. A classic immunohistochemical panel of CK7,
CK20, and CDx2 is usually considered helpful in indicat-
ing tumor origin, but unfortunately shows overlap in ex-
pression patterns in MOC and mMC [10–13]. Also, partic-
ularly MOC arising from teratomas are known to express a
more gastrointestinal phenotype [14].
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Macroscopic features as size and laterality have also
been investigated. Unilaterality and large size is indicative
of MOC, while bilaterality is more suggestive of mMC
[7]. We have shown earlier that colorectal mMC are uni-
lateral in almost 60% of cases [1]. Despite this, these
macroscopic features have been proposed by various stud-
ies as discriminators between MOC and mMC. Seidman
et al. proposed an algorithm designating unilateral tumors
smaller than 10 cm and bilateral tumors as mMC, and
unilateral tumors of at least 10 cm in size as MOC [2].
Another algorithm by Yemelyanova et al. used a different
size cut off point of 13 cm [15]. These algorithms classi-
fied 90% and 87% of tumors correctly, and yielded a
sensitivity for mMC of 94.7% and 82%, respectively.
These algorithms should focus on a low rate of false neg-
ative patients with mMC, since misdiagnosis will lead to
withholding the diagnostic workup to identify a primary
tumor elsewhere with important therapeutic and prognos-
tic consequences.
Previous studies were performed on relatively small co-
horts.We aimed to evaluate these algorithms on a larger tumor
cohort and improve them where possible.
Materials and methods
Case selection: primary mucinous ovarian tumors
The nationwide network and registry of histopathology and
cytopathology in the Netherlands (PALGA) codes and
saves pathology reports in the Netherlands from 1971 with
nationwide coverage from 1991 [16]. We performed a na-
tionwide search for primary (micro-)invasive mucinous
ovarian carcinomas diagnosed between 2000 and 2011 in
the PALGA database obtained by complete resection. All
tumors of non-mucinous, mixed, and uncertain histology
were excluded. Tumors labeled Krukenberg tumors were
excluded from the MOC group, since this term refers to
metastatic signet ring cell carcinomas [17]. Tumors asso-
ciated with pseudomyxoma peritonei (PMP) were exclud-
ed. Any tumors of which origin was reported to be uncer-
tain were excluded. History of eligible patients was re-
quested at PALGA, and patients with a history of a gastro-
intestinal tumor regardless of histology, a mucinous tumor
regardless of location, and an adenocarcinoma NOS locat-
ed in the genital tract were excluded. For each patient, we
extracted the following items: age at time of diagnosis,
origin (primary or metastasis), histological subtype,
laterality, and size of the ovarian tumor. In case of bilateral
tumors, both largest and smallest sizes were registered if
available. In case of unilateral tumors, size was scored as
largest. If only one ovary was resected or reported, we
considered the tumor to be unilateral.
Case selection: mucinous tumors metastatic
to the ovary
A database containing mMC was created earlier. Details
about criteria for this database are described elsewhere
[1]. From this database, we extracted all tumors metastatic
to the ovary with histological proof of extra-ovarian origin
and mucinous histology. Additional macroscopic data were
requested at PALGA. Cases were excluded from this data-
base if tumor size mentioned in additional macroscopy and
conclusion was discrepant or if macroscopy contained any
information making it uncertain whether a tumor was pri-
mary or metastatic. For cases in this dataset, we addition-
ally extracted location of the primary tumor.
These data were combined to create a database containing
both MOC and mMC.
Statistical analysis
For cases with no data available for laterality or size,
multiple imputation was applied to estimate these values
to maintain cohort size and to avoid biased estimates in
the regression analyses. With this technique, multiple
complete datasets are created by drawing a value for the
missing values based on the estimated distribution. Each
dataset is analyzed and the results are combined [18].
Imputed variables and variables used for imputation are
shown in Online Resource 1. Twenty imputated datasets
were created.
We applied the algorithms described earlier on our da-
tabase to evaluate sensitivity, specificity, and number of
correctly classified cases.
To identify discriminating factors, logistic regression
was carried out for each step in the algorithm creation
process. Our approach was based on a high sensitivity
for mMC.
For creating nomogram scores, regression coefficients
B were calculated using logistic regression with the con-
tinuous variables age and largest size. For size and age, a
score Score(size + age) was calculated for nomogram crea-
tion. Details are found in Online Resource 2.
Statistical analysis was performed using IBM SPSS
statistics version 20.0. For comparison of means, two-
tailed t tests were performed, for comparison of frequency
distributions between categorical data χ2 tests were per-
formed. A p value < 0.05 was considered statistically sig-
nificant. ROC curves were used to determine optimal cut-
off points.
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Results
Features of primary mucinous ovarian tumors
and tumors metastatic to the ovary
A total of 735 MOC and 1018 mMC were identified.
Laterality data was missing for 52 MOC (7.1%) and 84
mMC (8.3%); largest size data were missing for 129 MOC
(17.6%) and 312 mMC (30.6%). Patients with MOC were
significantly younger than patients with mMC (54.6 vs.
59.6 years; p < 0.01) and had larger tumors (19.0 vs.
12.0 cm; p < 0.01). Size and age distribution among patients
with MOC and mMC are depicted in Fig. 1. Patients with
MOC had unilateral tumors in 662 cases (90.1%) vs. 73
(9.9%) bilateral tumors, whereas patients with mMC had bi-
lateral tumors in 508 cases (49.9%) and unilateral in 510 cases
(50.1%) (p < 0.001). Signet ring cell carcinomas were more
often metastatic than primary (122 (98.4%) vs. 2 (1.6%);
p < 0.001). Bilateral tumors were more often metastatic than
primary (508 (87.4%) vs. 73 (12.6%); p < 0.001), whereas
unilateral tumors were primary in 662 cases (56.5%) and were
metastatic in 510 cases (43.5%). Characteristics before and
after imputation are shown in Tables 1 and 2, showing that
this led to no significant changes.
Comparison to earlier studies
Seidman et al. [2] classified tumors as MOC if they were uni-
lateral and ≥ 10 cm. In our cohort, 15.4% of tumors < 10 cm
were primary and 84.6%was metastatic. Tumors ≥ 10 cm were
primary in 52.5% and were metastatic in 47.5%. MMCwere <
10 cm in 41.5% and ≥ 10 cm in 58.5%. Of MOC, this was
10.5% and 89.5%, respectively. On our data, the Seidman al-
gorithm has a sensitivity of 72.5% and a specificity of 82.4%
and of all 76.6% tumors were classified correctly.
Yemelyanova et al. [15] used 13 cm as a size cutoff point.
In our cohort, tumors < 13 cm were primary in 26.8% and
were metastatic in 73.2%. Tumors ≥ 13 cm were primary in
56.9% and were metastatic in 43.1%. MMC were < 13 cm in
56.8% and ≥ 13 cm in 43.2%. Of MOC, this was 21.1% and
78.9%, respectively. On our data, the Yemelyanova algorithm
has a sensitivity of 79.9% and a specificity of 73.6% and of all
tumors 77.2% were classified correctly.
Further test details for both algorithms are shown in
Table 3.
Optimizing algorithm
Logistic regression identified age, largest size, histology, and
laterality as significant independent predicting factors for
distinguishing MOC from mMC. Regression coefficients,
odds ratios, and 95% confidence intervals are displayed in
Online Resource 2.
Signet ring cell histology compared to non-signet ring cell
histology showed a sensitivity of only 12.0%, but a specificity
of 99.7% for indicating metastasis, with a positive predictive
value for metastasis of 98.4%. Comparing bilaterality to
unilaterality as a next step, after excluding signet ring cell
carcinomas, shows a sensitivity of only 48.1%, but a specific-
ity of 90.0% for indicating metastasis, with a positive predic-
tive value of 85.5%.
Based on the remaining cases, areas under the curve (AUC)
for largest size and age as a determinant of origin were 0.78
and 0.64, respectively. To test a combination of these two
variables, logistic regression including age and largest size
was carried out and rendered regression coefficient Bsize
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Fig. 1 Frequency distribution for largest size (a) and age (b)
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0.154 and Bage − 0.033, respectively (p < 0.001 for both vari-
ables). Larger tumors and lower age tended to be associated
with primary tumors, although distributions showed too much
overlap to be used as a solitary determinant (see Fig. 1). The
largest size range was 1 to 60 cm and age range was 15 to
95 years. Exact calculations can be found in Online Resource
3. Final scores for size and age can be found in
Online Resources 4 and 5, respectively.
The ROC curve for Score(size + age) showed an AUC of 0.81
(see Online Resource 6), and for Score(size) or Score(age) again
0.78 and 0.64, respectively. Based on the AUC, Score(size + age)
was considered superior to Score(size) or Score(age) separately.
An optimal cutoff point for the sum of these scores was
determined as 6.1 using the ROC curve coordinates. A nomo-
gram based on this score is shown in Fig. 2. The final algo-
rithm as depicted in Fig. 3 shows a sensitivity and specificity
of 90.1% and 59.0%, respectively, and 77.1% of tumors were
classified correctly. Details are shown in Table 3.
Table 1 Features of primary and metastatic mucinous ovarian carcinomas before imputation, age, and size expressed as mean
Parameter Primary % Metastasis % p value
Age 54.6 ± 15.1 59.6 ± 13.1 < 0.001
Histology Mucinous 733 45.0 896 55.0 < 0.001
Signet-ring cell 2 1.6 122 98.4
Location primary tumor Appendix 97 9.5
Bladder 2 0.2
Breast 3 0.3
Cervix 2 0.2
Endometrium 4 0.4
Colon 748 73.5
Duodenum 1 0.1
Small intestine 22 2.2
Pancreas 17 1.7
Bile ducts/gallbladder 14 1.4
Esophagus 7 0.7
Stomach 100 9.8
Urachus 1 0.1
Laterality Left 284 56.6 218 43.4 < 0.001
Right 330 54.1 280 45.9
Bilateral 69 13.7 436 86.3
Unknown 52 38.2 84 61.7
Size (largest) 18.9 ± 7.9 11.6 ± 6.4 < 0.001
Total 735 41.9 1018 58.1
Table 2 Size and laterality of primary and metastatic mucinous ovarian
carcinomas after imputation
Parameter Primary % Metastasis % p value
Laterality Left 307 57.8 224 42.2 < 0.001
Right 355 55.4 286 44.6
Bilateral 73 12.6 508 87.4
Unknown 0 0
Size (largest) 19.0 12.0 < 0.001
Total 735 41.9 1018 58.1
Table 3 Results of algorithms on current tumor cohort
Study Origin
Primary Metastasis
Seidman et al. Primary 604 280
Metastasis 131 738
Sensitivity 72.4%
Specificity 82.2%
Yemelyanova et al. Primary 541 205
Metastasis 194 813
Sensitivity 79.9%
Specificity 73.6%
Current study Primary 434 101
Metastasis 301 917
Sensitivity 90.1%
Specificity 59.0%
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Discussion
MOC are often difficult to distinguish from mMC, since mor-
phological and immunohistochemical features are unsatisfac-
tory differentiators. In the current study, we composed the
largest database of MOC and mMC to our knowledge to eval-
uate size and laterality as predictors of tumor origin. Patients
withMOCwere significantly younger, andMOCs were larger
and more often unilateral, which is in line with earlier findings
[7, 8]. We compared our data to earlier algorithms using these
features and optimized the algorithm by adding presence of
signet ring cells and patient age.
Earlier algorithms, based on small patient cohorts, of only
50, 194, and 68 tumors, respectively, solely used laterality and
size of the tumors [2, 15, 19]. Application of a 10-cm cutoff in
two studies resulted in a sensitivity of 83–95% [2, 19]; adjust-
ment of the cutoff to 13 cm showed a 82% sensitivity [15].
The populations used in these studies were heterogeneous
because of diverse inclusion criteria regarding tumors of un-
certain primary site and endometrioid and signet ring cell
histology. Signet ring cell carcinoma can be of primary ovar-
ian origin, but this is extremely rare [20]. In our cohort, less
than 2 per 100 signet ring cell carcinomas were MOC.
Applying the earlier algorithms to our cohort yielded far lower
sensitivity compared to our algorithm, suggesting that our
algorithm including signet ring cells and a combination of
relative values for tumor size and patient age renders superior
results. Interestingly, sensitivity was also lower than found in
the cohorts used in their original studies. Since the number of
correctly classified tumors in general was comparable (ap-
proximately 77%), these differences seem to be mainly the
consequence of different composition of the cohorts. This
can be explained by several factors. Firstly, the distribution
of primary tumors in the mMC group differs between study
populations, which may be due to geographical differences.
Secondly, revision of cases in our cohort is not feasible due to
large numbers, but since it concerns a nation-wide population-
based cohort, it reflects daily practice. Thirdly, patients from
tertiary referral centers include a selection of patients, with
unusual cases, as can be observed in the Yemelyanova study,
that included as much as 35% consultation cases.
No bilateral MOC were observed in the Yemelyanova co-
hort, as opposed to both our cohort (8.9% bilateral MOC) and
the cohorts of Seidman and Khunarmonpong (17% and
12.5%, respectively) [2, 19]. Bilaterality of MOC might be
explained by MOC metastasizing from one ovary to the con-
tralateral ovary without this being recognized or reported as
such. The possibility of a misdiagnosed mMC cannot be fully
excluded. In the current study, the number of bilateral mMC
was much lower with 49.9%, most likely due to the large
number of colorectal metastases in our cohort which are
known for their ability to present as large, unilateral metasta-
ses [21]. Another difference is that Yemelyanova et al. also
included atypical proliferative mucinous (borderline) tumors
(APMTs) and tumors associated with PMP. The latter may
have led to a higher number of bilateral metastatic tumors,
since we discarded cases associated with PMP. Ovarian in-
volvement of pseudomyxoma peritonei has been shown to
Fig. 2 Nomogram based on Score(size + age). By applying patient age en tumor size to the corresponding axes and extrapolating a line through these points
to the lower axis, final Score(size + age) can be determined
Fig. 3 Final algorithm for distinguishing primary mucinous carcinomas
and carcinomas metastatic to the ovary using parameters signet ring cells,
laterality, patient age, and tumor size. For calculating Score(size + age), use
the nomogram displayed in Fig. 2
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be almost invariably of appendiceal origin, the only potential
but rare exception being a mucinous neoplasm originating in
an ovarian teratoma [14, 22–24]. Hence, cases associated with
pseudomyxoma peritonei pose less diagnostic problems.
Also, pathological classification of pseudomyxoma peritonei
remains problematic [25–27]. We also excluded APMTs to
prevent contamination of the MOC group with misclassified
mMC, since APMTs would not generally trigger workup for
metastasis from a primary tumor elsewhere. Especially pan-
creatic tumors are known for their capability to mimic APMTs
of the ovary. In addition, we ideally wanted to include carci-
nomas according to WHO criteria, but for micro-invasion
varying criteria are used and the exact proportions of invasive
foci were rarely reported. To prevent exclusion of actual inva-
sive carcinomas falsely diagnosed as micro-invasive, we did
include tumors reported to be micro-invasive.
In our cohort, size and patient age were significantly differ-
ent between MOC an mMC, but showed too much overlap to
be discriminating by themselves. We integrated age in the
existing algorithm, using it in direct combination with size.
The optimized algorithm based on our own cohort led to a
sensitivity and specificity of 90.1% and 59.0%, respectively.
Since misdiagnosing an mMC as an MOC has greater conse-
quences for further diagnostic workup and therapy than vice
versa, our approach was based on a high sensitivity for diag-
nosing mMC and yielding a low number of false negative
patients. This reduces the possibility of patients ultimately re-
ceiving inappropriate treatment for their disease, which differs
considerably. Primary mucinous ovarian carcinomas are pri-
marily treated surgically, followed by a combination of
paclitaxel- and platinum-based chemotherapy in case of ad-
vanced stage disease. In case of mMC, patients will be surgi-
cally treated if possible, followed by up to triple therapy with
platinum-based chemotherapy, fluoropyrimidines, irinotecan,
and the addition of targeted therapy if indicated.With a positive
predictive value of 75.3% for mMC, almost 25% of patients
will undergo unnecessary diagnostic workup. In the intraoper-
ative setting the algorithm has limited value, since low speci-
ficity might lead to denial of surgical staging of patients with
MOC when a mMC is reported. However, in practice, manual
exploration of the abdominal cavity is performed, which—
given the high incidence of both colorectal and appendiceal
metastasis—can lead to clinical confirmation of metastasis. In
absence of this clinical confirmation, limited staging can be
performed, and the surgeon can consider to perform (limited)
surgical staging based on the intraoperative suspicion.
In this study, we used multiple imputations to replace
values missing at random (MAR) by values drawn from an
estimated distribution of the variable in question, a method
used frequently in biomedical research [28–30]. This tech-
nique is based on the general statistical principle that every
subject in a randomly chosen sample can be replaced by a new
subject that is randomly chosen from the same source
population. Analysis of available cases when values are
MAR is no longer based on a random sample from the source
population, leading to severely biased study associations and
incorrect standard errors. This can be reliably overcome by
multiple imputations, rendering this method superior to com-
plete cases analysis [31, 32]. The imprecision caused by the
fact that the distribution of the variables with missing values is
estimated, is taken into account by creating multiple
imputated datasets and combining these to obtain a pooled
estimate of the parameters and standard errors [32]. The ran-
dom subset of which new subjects are chosen or imputed is
defined by the already known characteristics (the variables
used for imputation). Using as many as six variables for im-
putation greatly reduces the influence of the technique on the
final result [33]. Our algorithm was not subjected to valida-
tion, since there is a lack of large validation sets for this type of
patient cohort. This might lead to overestimated accuracy,
although due to the large sample size this overestimation will
be relatively small.
Lack of a gold standard for classifying MOC and mMC
causes difficulties in creating study populations in all reported
studies to date. We did not revise the cases included in our
cohort. We used a proven primary tumor elsewhere as evi-
dence for metastatic ovarian disease, which can be considered
an objective criterion. The probability of patients presenting
with both a MOC and a gastrointestinal tumor simultaneously
seems very low. It is conceivable that metastatic disease may
have been falsely classified as a primary ovarian tumor, if no
diagnostic workup took place because of initial misdiagnosis
or if patients did not undergo surgery of the primary tumor.
However, the large sample size reduces the influence of these
factors to some extent.
Evaluation of histological and immunohistochemical features
as well as clinical and imaging data was impeded by the large
sample size and therefore considered beyond the scope of this
study.Microscopic features observedmore often inMOC are for
example expansive growth patterns or presence of precursor
lesions, whereas features such as infiltrative growth, dirty necro-
sis, lymph vessel invasion, and surface involvement are seen
more often in mMC [7–9]. Multiple studies have shown that
MOC and mMC show overlap in classic immunohistochemical
expression patterns [10–13]. Despite overlap of these morpho-
logical and immunophenotypical features between MOC and
mMC, integrating histological and immunohistochemical fea-
tures will very probably further optimize the described algo-
rithm. Also, recently discovered markers may prove superior to
the existing combinations, such as SATB2 which is a promising
new marker with high specificity for gastrointestinal origin
[34–36]. This algorithm can be useful for frozen section, al-
though strictly for patients with unilateral salpingo-
oophorectomy it may be misleading since microscopic involve-
ment of the contralateral ovary may not be macroscopically vis-
ible preoperatively and therefore prevent bilateral resection.
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In conclusion, our algorithm has a higher sensitivity of
90.1% for diagnosing mMC compared to earlier reported al-
gorithms, hereby validating these earlier approaches on a large
cohort and adding patient age and tumor histology as contrib-
uting factors. Macroscopic and demographic features as pro-
posed in the current study strongly aid in decision making, but
algorithms as described here should be regarded as helpful
rather than conclusive tools. Ultimately, differentiating MOC
from mMC is a task beyond the responsibility of the patholo-
gist alone and should be based on careful integration of pre-
operative workup including imaging and laboratory results
and macroscopic, histological, and immunophenotypical tu-
mor features and requires accurate and thorough multidisci-
plinary communication.
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